Royal Bank of Canada reiterated their outperform rating on shares of 4basebio (LON:4BB - Free Report) in a research report released on Thursday morning, Marketbeat Ratings reports. They currently have a GBX 1,600 ($20.78) price objective on the stock.
4basebio Price Performance
Shares of 4BB stock traded up GBX 18 ($0.23) during trading hours on Thursday, reaching GBX 1,150 ($14.94). The company's stock had a trading volume of 70 shares, compared to its average volume of 769. 4basebio has a fifty-two week low of GBX 901 ($11.70) and a fifty-two week high of GBX 1,820 ($23.64). The firm's 50 day simple moving average is GBX 1,166.17 and its 200-day simple moving average is GBX 1,259.02. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47. The company has a market capitalization of £147.32 million, a price-to-earnings ratio of -1,474.36 and a beta of 1.09.
Insider Buying and Selling at 4basebio
In related news, insider Amy Walker acquired 1,151 shares of the company's stock in a transaction that occurred on Friday, February 28th. The stock was acquired at an average price of GBX 1,120 ($14.55) per share, with a total value of £12,891.20 ($16,743.99). Company insiders own 68.44% of the company's stock.
4basebio Company Profile
(
Get Free Report)
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.
Read More
Before you consider 4basebio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4basebio wasn't on the list.
While 4basebio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
